Looking to fill several positions: Oncology, Infectious Diseases, Clinical Coordinator, Clinical Pharmacist days, Anticoagulation. JOB DESCRIPTION: Collaborates with departmental and patient care lead...

Preliminary results from a large, randomized clinical trial for patients ages 16 to 60 with previously untreated acute myeloid leukemia (AML), a cancer of the blood and bone marrow, show that patients who received a high dose of a commercially available chemotherapy drug, daunorubicin, during initial therapy lived longer than patients who received a standard dose of the same drug. Daunorubicin, a drug originally approved for use by the U.S.

Cancer patients - with their weakened immune systems - are particularly vulnerable when the cold and flu season hits. To help, the U.S. National Cancer Institute (NCI) is sponsoring a landmark trial to see whether a unique Canadian cold remedy - COLD-FX - can help.

Chronic Lymphocytic Leukemia (CLL) is a disease of the B lymphocytes of the immune system. Under normal conditions, B lymphocytes (or B cells) play an important role in battling infection. CLL is a disease manifested by uncontrolled growth of these B lymphocytes. In this month's issue of

In the November 15th issue of G&D, Dr. Kenneth Dorshkind and colleagues at the David Geffen School of Medicine (UCLA) have identified two genes - p16(Ink4a) and Arf - that sensitize lymphoid progenitor cells to the effects of aging, and confer resistance to leukemogenesis. Hematopoiesis (the development of blood cells) entails two main pathways: myelopoiesis (the formation of the red and white myeloid cells) and lymphopoiesis (the formation of B- and T-cells).

Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been "cured" by a bone marrow transplant given to treat his acute myeloid leukemia.

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML).